Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation

Cell

Volumn 112, Issue 6, 2003, Pages 779-791

  Leng, Roger P ^a   Lin, Yunping ^a   Ma, Weili ^a   Wu, Hong ^b   Lemmers, Benedicte ^a,c   Chung, Stephen ^a   Parant, John M ^d   Lozano, Guillermina ^d   Hakem, Razqallah ^a,c   Benchimol, Samuel ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MDM2; PROTEIN P53; PROTEIN PIRH2; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING SITE; CONTROLLED STUDY; ENZYME ACTIVITY; FEEDBACK SYSTEM; GENE CONTROL; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TRANSACTIVATION;

ANIMALIA;

EID: 0037459377     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0092-8674(03)00193-4     Document Type: Article

References (42)

1. Adler V., Pincus M.R., Minamoto T., Fuchs S., Bluth M.J., Brandt-Rauf P.W., Friedman F.K., Robinson R.C., Chen J.M., Wang X.W.et al. Conformation-dependent phosphorylation of p53. Proc. Natl. Acad. Sci. USA. 94:1997;1686-1691.
2. Appella E., Anderson C.W. Post-translational modifications and activation of p53 by genotoxic stresses. Eur. J. Biochem. 268:2001;2764-2772.
3. Banks L., Matlashewski G., Crawford L. Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur. J. Biochem. 159:1986;529-534.
4. Barak Y., Juven T., Haffner R., Oren M. Mdm2 expression is induced by wild type p53 activity. EMBO J. 12:1993;461-468.
5. Beitel L.K., Elhaji Y.A., Lumbroso R., Wing S.S., Panet-Raymond V., Gottlieb B., Pinsky L., Trifiro M.A. Cloning and characterization of an androgen receptor N-terminal-interacting protein with ubiquitin-protein ligase activity. J. Mol. Endocrinol. 29:2002;41-60.
6. Borden K.L.B. RING domains. master builders of molecular scaffolds? J. Mol. Biol. 295:2000;1103-1112.
7. Chen J., Marechal V., Levine A.J. Mapping of the p53 and mdm-2 interaction domains. Mol. Cell. Biol. 13:1993;4107-4114.
8. El-Deiry W.S., Kern S., Pietenpol J.A., Kinzler K.W., Vogelstein V. Definition of a consensus binding site for p53. Nat. Genet. 1:1992;45-49.
9. Fang S., Jensen J.P., Ludwig R.L., Vousden K.H., Weissman A.M. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J. Biol. Chem. 275:2000;8945-8951.
10. Fuchs S.Y., Adler V., Buschmann T., Yin Z., Wu X., Jones S.N., Ronai Z. JNK targets p53 ubiquitination and degradation in nonstressed cells. Genes Dev. 12:1998;2658-2663.
11. Gu J., Chen D., Rosenblum J., Rubin R.M., Yuan Z. Identification of a sequence element from p53 that signals for Mdm2-targeted degradation. Mol. Cell. Biol. 20:2000;1243-1253.
12. Harlow E., Crawford L.V., Pim D.C., Williamson N.M. Monoclonal antibodies specific for simian virus 40 tumor antigens. J. Virol. 39:1981;861-869.
13. Haupt Y., Maya R., Kazaz A., Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 387:1997;296-299.
14. Honda R., Yasuda H. Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase. Oncogene. 19:2000;1473-1476.
15. Honda R., Tanaka H., Yasuda Y. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420:1997;25-27.
16. Jackson M.W., Berberich S.J. MdmX protects p53 from Mdm2-mediated degradation. Mol. Cell. Biol. 20:2000;1001-1007.
17. Johnson P., Chung S., Benchimol S. Growth suppression of friend virus-transformed erythroleukemia cells by p53 protein is accompanied by hemoglobin production and is sensitive to erythropoietin. Mol. Cell. Biol. 13:1993;1456-1463.
18. Jones S.N., Roe A.E., Donehower L.A., Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature. 378:1995;206-208.
19. Juven T., Barak Y., Zauberman A., George D.L., Oren M. Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene. 8:1993;3411-3416.
20. Koepp D.M., Harper J.W., Elledge S.J. How the cyclin became a cyclin. regulated proteolysis in the cell cycle Cell. 97:1999;431-434.
21. Kubbutat M.H.G., Jones S.N., Vousden K.H. Regulation of p53 stability by Mdm2. Nature. 387:1997;299-303.
22. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell. 88:1997;323-331.
23. Lorick K.L., Jensen J.P., Fang S., Ong A.M., Hatakeyama S., Weissman A.M. RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination. Proc. Natl. Acad. Sci. USA. 96:1999;11364-11369.
24. Luo J., Su F., Chen D., Shiloh A., Gu W. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature. 408:2000;377-381.
25. Luo J., Nikolaev A.Y., Imai S.I., Chen D., Su F., Shiloh A., Guarente L., Gu W. Negative control of p53 by Sir2α promotes cell survival under stress. Cell. 107:2001;137-148.
26. Momand J., Zambetti G.P., Olson D.C., George D., Levine A.J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 69:1992;1237-1245.
27. Montes de Oca Luna R., Wagner D.S., Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature. 378:1995;203-206.
28. Oliner J.D., Pietenpol J.A., Thiagalingam S., Gyuris J., Kinzler K.W., Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumor suppressor p53. Nature. 362:1993;857-860.
29. Parant J., Chavez-Reyes A., Little N.A., Yan W., Reinke V., Jochemsen A.G., Lozano G. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat. Genet. 29:2001;92-95.
30. Prives C., Manley J.L. Why is p53 acetylated? Cell. 107:2001;815-818.
31. Querido E., Blanchette P., Yan Q., Kamura T., Morrison M., Boivin D., Kaelin W.G., Conaway R.C., Conaway J.W., Branton P.E. Degradation of p53 by adenovirus E4orf6 and E1B55K proteins occurs via a novel mechanism involving a Cullin-containing complex. Genes Dev. 15:2001;3104-3117.
32. Resnick-Silverman L., St. Clair S., Maurer M., Zhao K., Manfredi J.J. Identification of a novel class of genomic DNA-binding sites suggests a mechanism for selectivity in target gene activation by the tumor suppressor protein p53. Genes Dev. 12:1998;2102-2107.
33. Scheffner M., Huibregtse J.M., Vierstra R.D., Howley P.M. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell. 75:1993;495-505.
34. Shaulian E., Zauberman A., Ginsberg D., Oren M. Identification of a minimal transforming domain of p53. negative dominance through abrogation of sequence-specific DNA binding Mol. Cell. Biol. 12:1992;5581-5592.
35. Shvarts A., Steegenga W.T., Riteco N., van Laar T., Dekker P., Bazuine M., van Ham R.C.A., van der Houven van Oordt W., Hateboer G., van der Eb A.J., Jochemsen A.G. Mdmx. a novel p53-binding protein with some functional properties of MDM2 EMBO J. 15:1996;5349-5357.
36. SIRT1 functions as an NAD-dependent p53 deacetylase. Cell. 107:2001;149-159.
37. Vogelstein B., Lane D., Levine A.J. Surfing the p53 network. Nature. 408:2000;307-310.
38. Vousden K.H. Activation of the p53 tumor suppressor protein. Biochim. Biophys. Acta. 1602:2002;47-59.
39. Wu X., Bayle J.H., Olson D., Levine A.J. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 7:1993;1126-1132.
40. Yang A., Kaghad M., Caput D., McKeon F. On the shoulders of giants. p63, p73 and the rise of p53 Trends Genet. 18:2002;90-95.
41. Yu J., Zhang L., Hwang P.M., Rago C., Kinzler K.W., Vogelstein B. Identification and classification of p53-regulated genes. Proc. Natl. Acad. Sci. USA. 96:1999;14517-14522.
42. Zhao R., Gish K., Murphy M., Yin Y., Notterman D., Hoffman W.H., Tom E., Mack D.H., Levine A.J. Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev. 14:2000;981-993.